A. Alva Et Al. , "Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361," ESMO Virtual Congress , vol.31, ELECTR NETWORK, 2020
Alva, A. Et Al. 2020. Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361. ESMO Virtual Congress , (ELECTR NETWORK).
Alva, A., Csoszi, T., ÖZGÜROĞLU, M., Matsubara, N., Geczi, L., Cheng, S. Y., ... Fradet, Y.(2020). Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361 . ESMO Virtual Congress, ELECTR NETWORK
Alva, A. Et Al. "Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361," ESMO Virtual Congress, ELECTR NETWORK, 2020
Alva, A. Et Al. "Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361." ESMO Virtual Congress , ELECTR NETWORK, 2020
Alva, A. Et Al. (2020) . "Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361." ESMO Virtual Congress , ELECTR NETWORK.
@conferencepaper{conferencepaper, author={A. Alva Et Al. }, title={Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361}, congress name={ESMO Virtual Congress}, city={}, country={ELECTR NETWORK}, year={2020}}